GADD 45β Inhibitors
GADD45β inhibitors form a diverse group of compounds designed to modulate the function of GADD45β, offering a valuable toolkit for researchers interested in dissecting its biology and understanding the intricate regulatory networks governing its function. While direct inhibitors are limited, several compounds demonstrate their efficacy by affecting critical cellular processes and signaling pathways associated with GADD45β. SB203580 and Trametinib are among the indirect inhibitors that impact GADD45β by disrupting the p38 MAPK and MAPK pathways, respectively. These compounds intervene in critical cellular processes, indirectly altering GADD45β function and emphasizing the interconnectedness between GADD45β and broader signaling cascades. Selective JNK inhibitors, such as SP600125 and SP0102, exert their effects by targeting the JNK signaling pathway, offering additional indirect avenues to influence GADD45β-associated processes. By modulating this essential signaling pathway, these compounds contribute to the intricate regulatory mechanisms governing GADD45β.
LY294002 and Wortmannin, as PI3K inhibitors, modulate GADD45β by disrupting the PI3K/Akt pathway. These compounds provide researchers with tools to explore the interplay between PI3K signaling and GADD45β function, adding depth to the understanding of GADD45β regulatory networks. Inhibitors such as Rapamycin, AZD8055, and U0126 target mTOR and MEK, respectively, impacting downstream pathways linked to GADD45β. By influencing these critical nodes in cellular signaling, these inhibitors provide insights into the regulatory mechanisms that govern GADD45β function and its integration into broader cellular processes. PD98059 and SB590885, inhibitors of MEK and p38 MAPK, respectively, indirectly impact GADD45β by altering the MAPK pathway. This adds to the diverse array of modulators that researchers can leverage to investigate the roles of GADD45β in various cellular contexts. SB216763, a GSK-3 inhibitor, influences GADD45β by targeting the Wnt signaling pathway. This specificity offers researchers a refined tool to study the nuances of GADD45β regulation and its interactions within cellular signaling networks.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580, a selective p38 MAPK inhibitor, indirectly influences GADD45β by disrupting the p38 MAPK signaling pathway. Inhibition of p38 MAPK by SB203580 interferes with downstream processes where GADD45β is involved, demonstrating its potential to affect GADD45β function by modulating the p38 MAPK-mediated pathway. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125, a JNK inhibitor, indirectly modulates GADD45β by targeting the JNK signaling pathway. Inhibition of JNK by SP600125 disrupts downstream processes where GADD45β is involved, illustrating its potential to affect GADD45β function by influencing the JNK-mediated pathway. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002, a PI3K inhibitor, indirectly influences GADD45β by targeting the PI3K/Akt signaling pathway. Inhibition of PI3K by LY294002 disrupts downstream processes involving GADD45β, demonstrating its potential to affect GADD45β function by modulating the PI3K/Akt-mediated pathway. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059, a MEK inhibitor affecting the MAPK pathway, indirectly influences GADD45β by disrupting the downstream signaling cascade. Through inhibition of MEK, PD98059 alters the MAPK pathway, potentially impacting GADD45β function by modulating the pathways associated with MAPK signaling. | ||||||
AZD8055 | 1009298-09-2 | sc-364424 sc-364424A | 10 mg 50 mg | $163.00 $352.00 | 12 | |
AZD8055, a dual mTORC1 and mTORC2 inhibitor, indirectly modulates GADD45β by targeting the mTOR signaling pathway. Inhibition of mTOR by AZD8055 disrupts downstream processes where GADD45β is involved, demonstrating its potential to affect GADD45β function by modulating the mTOR-mediated pathway. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin, an mTOR inhibitor, indirectly modulates GADD45β by targeting the mTOR signaling pathway. Inhibition of mTOR by Rapamycin disrupts downstream processes where GADD45β is involved, demonstrating its potential to affect GADD45β function by modulating the mTOR-mediated pathway. | ||||||
SB 590885 | 405554-55-4 | sc-363287 sc-363287A | 10 mg 50 mg | $223.00 $942.00 | ||
SB590885, a selective p38 MAPK inhibitor, indirectly influences GADD45β by disrupting the p38 MAPK signaling pathway. Inhibition of p38 MAPK by SB590885 interferes with downstream processes where GADD45β is involved, demonstrating its potential to affect GADD45β function through the modulation of the p38 MAPK-mediated pathway. | ||||||
Trametinib | 871700-17-3 | sc-364639 sc-364639A sc-364639B | 5 mg 10 mg 1 g | $114.00 $166.00 $947.00 | 19 | |
Trametinib, a MEK inhibitor affecting the MAPK pathway, indirectly influences GADD45β by disrupting the downstream signaling cascade. Through inhibition of MEK, Trametinib alters the MAPK pathway, potentially impacting GADD45β function by modulating the pathways associated with MAPK signaling. | ||||||
SB-216763 | 280744-09-4 | sc-200646 sc-200646A | 1 mg 5 mg | $71.00 $202.00 | 18 | |
SB216763, a GSK-3 inhibitor, indirectly modulates GADD45β by targeting the Wnt signaling pathway. Inhibition of GSK-3 by SB216763 disrupts downstream processes involving GADD45β, illustrating its potential to affect GADD45β function by influencing the Wnt-mediated pathway. | ||||||